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In the process of drug development, in vitro studies
do not always adequately predict human-specific
drug responsiveness in clinical trials. Here, we
applied the advantage of human iPSC-derived neu-
rons, which offer human-specific drug responsive-
ness, to screen and evaluate therapeutic candidates
for Alzheimer’s disease (AD). Using AD patient neu-
rons with nearly 100% purity from iPSCs, we estab-
lished a robust and reproducible assay for amyloid
b peptide (Ab), a pathogenic molecule in AD, and
screened a pharmaceutical compound library.
We acquired 27 Ab-lowering screen hits, prioritized
hits by chemical structure-based clustering, and
selected 6 leading compounds. Next, to maximize
the anti-Ab effect, we selected a synergistic combi-
nation of bromocriptine, cromolyn, and topiramate
as an anti-Ab cocktail. Finally, using neurons from fa-
milial and sporadic AD patients, we found that the
cocktail showed a significant and potent anti-Ab ef-
fect on patient cells. This human iPSC-based plat-
form promises to be useful for AD drug development.
INTRODUCTION
Human induced pluripotent stem cell (iPSC) technology has
revolutionized drug discovery research (Shi et al., 2016) by mak-
ing it possible to produce diseased cells from patients in vitro.
In the research field of neurological diseases, direct biopsy of
affected tissues from patients causes irreversible injury; there-
fore, cellular and animal models generated by the transduction
and overexpression of disease-causative genes have been2304 Cell Reports 21, 2304–2312, November 21, 2017 ª 2017 The A
This is an open access article under the CC BY-NC-ND license (http://widely used for drug discovery research. However, recent
studies have elucidated a large difference in drug responsive-
ness between human iPSC-derived cells and cancer cell lines
(Liu et al., 2014; Mertens et al., 2013; Paull et al., 2015; Yahata
et al., 2011). In the process of drug development, the total suc-
cess rate from hit compounds to final launch is nearly 4.1%, ac-
cording to some estimates (Paul et al., 2010), and is only 11.6%
at clinical trial stages, even after successful preclinical studies.
The cause of these low success rates in drug development
may, at least partially, be attributed to a difference in drug
responsiveness between human beings and other model
animals and/or various drug dosages and transgenes that
mimic the disease conditions. To minimize this gap, patient-
derived iPSCs could be a promising resource for pharmacolog-
ical research. Here, we modified direct conversion technology
(Szabo et al., 2010; Zhang et al., 2013) for neuronal cells from hu-
man iPSCs (induced neurons: iNs) and achieved a neuronal cell
culture with nearly 100%purity after only a 1-week differentiation
period from iPSCs. This extremely pure and rapid method of
neuronal differentiation can eliminate the variant efficiency of dif-
ferentiation among iPSC clones (Onder and Daley, 2012; Tha-
tava et al., 2013) and is more suitable for modeling a pathological
condition and compound screening.
We applied this differentiationmethod to compound screening
for Alzheimer’s disease (AD), the most common cause of elderly
dementia. One of the neuropathological hallmarks of AD is the
formation of extracellular amyloid plaques that are composed
of aggregated amyloid b peptides (Abs) (Powers, 1997; Selkoe,
2004). Extensive studies of human genetics, neuropathology,
andmodel animals indicate that the accumulation of Abs is a trig-
gering event that initiates a long-term pathological cascade of
AD and eventually leads to dementia (Hardy and Selkoe, 2002;
Selkoe, 2002). Ab is produced by sequential cleavages of amy-
loid precursor protein (APP) by b-site APP cleaving enzyme 1
(BACE1) and g-secretase, and these two enzymes have beenuthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Transient NGN2 Expression Converts iPSCs into Cortical Neurons
(A) Schema of the differentiation system for iPSC-derived cortical neurons by using the piggyBac vector coding human NGN2 gene, the compound-screening
platform, and the in vitro trials.
(B) A generated FAD1-iPSC line expressed the pluripotency markers TRA1-60 (green) and NANOG (red). Scale bar, 200 mm.
(C) Day 8 FAD1 neurons expressed excitatory cortical neuron markers. Left: MAP2 (green) and SATB2 (red). Right: VGLUT1 (green) and TBR2 (red). Scale bars,
200 mm.
(D) Purity of day 8 neurons.
Data indicate mean ± SD (n = 3 for each clone).the most important targets for disease-modifying drugs of AD.
However, strong inhibition of g-secretase widely perturbs the
processing of numerous endogenous substrates important for
physiological functions other than APP, and it has caused
serious side effects after long-term treatment (Filser et al.,
2015). After the failure in recent clinical trials of g-secretase
inhibitor, mainly due to on-target side effects in humans (De
Strooper, 2014), BACE1 was considered as a more preferable
target for anti-Ab drugs, and several trials of BACE1 inhibitors
(BSIs) have been conducted (Bar~ao et al., 2016; Vassar et al.,
2014). However, in vivo studies, based on BACE1 null mice or
BSI treatment have revealed that BACE1 plays roles in several
essential neural phenomena, including myelination, ion channel
activities, neuronal migration, neuronal excitation, astrogenesis,
and muscle spindle activity, among others (Cheret et al., 2013;
Hu et al., 2016). Thus, the safety profiles of BSIs should be seri-
ously considered and closely monitored (Bar~ao et al., 2016; Yan,
2016). Furthermore, positron emission tomography (PET) imag-
ing of amyloid and cerebrospinal fluid (CSF) biomarkers, such
as the Ab42/40 ratio, has shown that amyloid burden in human
brains begins about 2 decades before the presentation of overt
clinical symptoms of AD (Jack et al., 2013). To prevent AD devel-
opment, anti-Ab therapy that is safe and applicable for the long
preclinical phase of AD without extensive amyloid burden is
desirable. To realize this ideal, we set up a compound screen
for a drug-repositioning approach, which has great advantages
for research and development costs and time due to enormous
post-marketing safety information.Here, we established a screening platform to explore anti-Ab
compound and combined hit compounds to maximize their
anti-Ab effects. Additionally, we conducted an in vitro evaluation
study by using iPSC-derived neurons from 13 individuals,
including familial and sporadic AD patients, and confirmed that
the combination of anti-Ab compounds could reduce Ab effi-
ciently in all participants beyond the differences in drug respon-
siveness amongmultiple individuals. The models and process of
this study should contribute to overcoming possible drawbacks
of drug discovery and development by a standard platform using
human iPSCs.
RESULTS
Robustly Differentiated Cortical Neurons Ensure Fine
Ab Phenotypes
Technically, the lack of consistent differentiation efficacy with a
high purity of iPSCs to neurons has been an issue for precise
modeling of the pathological condition and subsequent drug
screening (Inoue et al., 2014). To overcome this issue, we utilized
direct conversion technology to differentiate human iPSCs into
cortical neurons (Davis et al., 1987; Vierbuchen et al., 2010) (Fig-
ure 1A). Direct neural conversion using lentiviral induction of neu-
rogenin 2 (NGN2) was reported to provide mature neurons with
75%–100% purity (MAP2 [microtubule-associated protein 2]-
positive cells for lentivirally infected GFP-positive cells) (Zhang
et al., 2013), but the total neuronal purity (neurons per total cells
in a dish) depends on the efficiency of the lentiviral infection. ToCell Reports 21, 2304–2312, November 21, 2017 2305
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Figure 2. Alzheimer’s Disease Patient Cortical Neurons Showed Ab Phenotypes, Corrected by Genome Editing
(A) Schema of genome editing for PSEN1 exon11, using the CRISPR-Cas9 system.
(B) Sanger-sequence data of the genome-corrected site in PSEN1 G384A.
(C) Ab phenotypes of iPSC-derived cortical neurons. Data indicate mean ± SD (n = 3 for each clone; *p < 0.05, Dunnett’s test for multiple comparisons to FAD1
PBMC origin).
(D) ELISA quantification of Ab species, altered by adding BSI-IV (b-secretase inhibitor), JNJ-40418677 (g-secretase modulator), or semagacestat (g-secretase
inhibitor). Plots show the results of serial 5-fold dilutions ranging from 1.6 nM to 25 mM of the respective compounds. Data indicate mean ± SD (n = 3 for each
concentration).transduce NGN2 into all cells in a dish, we established human
iPSC clones with doxycycline-inducible human NGN2 from a
familial AD patient bearing a heterozygous G384A mutation of
the PSEN1 gene, which encodes presenilin-1, by using piggyBac
transposon (Figure 1B) (Kim et al., 2016). We tested 5-day
NGN2 expression via genome-integrated piggyBac vector and
found that the cortical neurons induced from iPSCs had
more than 96% purity (Figures 1C and 1D) and expressed no
remaining exogenous NGN2 (Figure S1A) on day 8. Further, the
induced cortical neurons were electrophysiologically functional
(Figure S1B).
Mutations of PSEN1 are known to increase the production of
Ab42 as a toxic Ab species, and the Ab42/40 ratio is an index
of Ab toxicity (Citron, 2010), compared with wild genotype
(Page et al., 2008). To confirm that the system developed in
this study can recapitulate the Ab phenotypes of PSEN1 muta-
tion precisely, we corrected the PSEN1 G384A mutation of
FAD1 by using CRISPR-Cas9 technology (Figures 2A and 2B).
Cortical neurons with a heterozygous G384A mutation in
PSEN1 produced a larger amount of Ab42 and showed a higher
Ab42/40 ratio compared to that of neurons after genome correc-
tion (Figure 2C). Recapitulated Ab phenotypes of FAD1 were
similar to those of different iPSC clones that originated from a
different type of FAD1 somatic cells (Figures 2C, S2A, and2306 Cell Reports 21, 2304–2312, November 21, 2017S2B). These results confirmed that our Ab assay can provide pre-
cise phenotypes of FAD and that it offers reproducible evaluation
of different iPSC clones. We also validated our assay system
by applying commercially available Ab production-modifying
compounds, including b-secretase inhibitor IV (BSI-IV), JNJ-
40418677 (second-generation g-secretase modulator: GSM),
and semagacestat (g-secretase inhibitor: GSI) as positive con-
trols and confirmed the inhibitory effects of the compounds
on Ab production (Figure 2D). On the other hand, paradoxically,
a low concentration of semagacestat increased Ab42, and
a low concentration of non-steroidal anti-inflammatory drugs
(NSAIDs), which are first-generation GSMs, failed to improve
Ab levels (Figure S2C), which is consistent with previous reports
(Liu et al., 2014; Mertens et al., 2013; Yahata et al., 2011). From
these results, we confirmed the establishment of a robust and
reproducible screening system to assess changes in Ab produc-
tion in response to test compounds.
Screening for Anti-Ab Compounds Using a
Pharmaceutical Compound Library
We screened a compound library that consists of 2 mM each of
1,258 pharmaceutical compounds and ran tests to find anti-Ab
compounds as a first-step screening (Figure 3A). We defined
0.1% DMSO as a baseline control, 2 mM BSI-IV as a positive
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Figure 3. First-Step Screening of a Pharmaceutical Compound Library
(A) Scatterplot graphs of the first-step screening. Fold changes comparedwith DMSO control were plotted according to each analyte, including Ab40 (blue), Ab42
(red), the Ab42/40 ratio (black), and surviving cells (gray), by adding hit compounds or positive control compounds. The 3SD variance of DMSO control groups is
indicated by the yellow band. Compounds causing less survival than 3SD of DMSO control are indicated by overlapping deep red dots. BSI, b-secretase inhibitor;
GSM, g-secretase modulator.
(B) Points represent the Z’ factor of each 96-well plate in the first-step screening.
(C) Criteria of the first-step screening.control for alteration in Ab40 production, and 2 mM JNJ-
40418677 as a positive control for alteration in Ab42 production
and the Ab42/40 ratio alteration in each assay using a 96-well-
plate. Through all screening sets, Z’ factor, an indicator of
screening feasibility and reproducibility, was suitably high—
more than 0.8—in each analyte (Figure 3B). The coefficient of
variation (%CV) of DMSO control in each assay plate was below
5% (Figure S3A). From these results, we could confirm that this
screening system successfully assessed dynamic Ab responses
and had low variability among the assay sets. We set the inclu-
sion criteria of the first-step screening at ‘‘more than threefold
of standard deviation values (3SD) of DMSO control in each an-
alyte’’ to collect a wide range of potential anti-Ab compounds
(below the yellow field in the Figure 3A graph of Ab40, Ab42,
and the Ab42/40 ratio). To leave out toxic compounds that could
ostensibly lead to Ab reduction from a decreased number of neu-
rons, we excluded compounds that caused cell survival to be
less than 3SD of DMSO control (red dots in Figure 3A). According
to the inclusion and exclusion criteria of the first-step screening,
we collected 129 compounds (Figure 3C; Data S1). In the next
step, to set stringent hit criteria, we tested the 129 compounds
on both FAD1 iPSC-derived neurons and another iPSC-derived
neurons, originating from peripheral blood mononuclear cells
(PBMCs) of FAD1 (named ‘‘PBMC origin’’). To confirm thescreening reproducibility, we measured again the anti-Ab
effects of 129 compounds at 1 mM each as the second-step
screening by plotting the fold-change in Ab42, a toxic Ab with
a higher propensity to form insoluble Ab in amyloid plaques of
AD brain (Walsh et al., 2002). We observed a high correlation be-
tween FAD1 fibroblast-origin and FAD1 PBMC-origin neurons
(Figure S3B). As a result, we could confirm the reproducibility
of the developed screening system between different iPSC
clones, and finally selected 27 screen hits that passed the inclu-
sion criteria of Ab42.
Chemical Structure Clustering Identified Six Lead
Compounds
The anti-Ab effects of the 27 screen hits were not as strong as
those of known BSIs, GSMs, or GSIs. To select synergistic com-
binations with maximal anti-Ab effects, we attempted to classify
and prioritize hit compounds based on fingerprinting of the com-
pound chemical structure (Figures 4A and S4A). The finger-
printing technique is widely used, and it successfully detects
structurally diverse active compounds of various similarity levels
(Gardiner et al., 2011; Vogt et al., 2010). We converted the chem-
ical structures of 129 compounds after the first-step screening
along with those of known BSIs, known GSMs, and known
GSIs (Data S2) into the fingerprinting format by using theCell Reports 21, 2304–2312, November 21, 2017 2307
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Figure 4. Chemical Structure Clustering Identified Six Lead Compounds
(A) Schema of the screening steps.
(B) Chemical-structure clustering classified 129 compounds, filtered by first-step screening, and 54 known Ab modifiers into 10 clusters, based on ECFP4
fingerprint similarity. The small table shows the number of compounds in each cluster, or known-Ab modifiers in each cluster, including BSIs or GSMs. BSI-St,
statin-derived BSI; BSI-Aq, aminoquinazoline-based BSI; GSM-Ns, NSAIDS-based GSMs; GSM-Im, GSM with imidazole structure.
(C) The Ab42 alteration ratio (versus DMSO control) of 27 screen hits is shown in the scatterplot graph according to each cluster. Each compound name of the top
two compounds to reduce Ab42 in each cluster is labeled.
(D) The selected six anti-Ab compounds decreased Ab production in a dose-dependent manner. Data indicate mean ± SD (n = 3 for each clone).Extended Connectivity Fingerprints method ([ECFP] version 4;
ECFP4), which is suitable for computer processing (Rogers
and Hahn, 2010). We divided various fingerprints into ten clus-
ters by calculating a measure of molecular similarity using the
Tanimoto coefficient (Tc), which is the gold standard in the che-
moinformatics field (Willett et al., 1998). Tc is a numerical mea-
sure of similarity ranging from zero (no fingerprint overlap) to
one (fingerprint identity). A high Tc among different compounds
has generally shown similar pharmacological activities in several
studies (Jasial et al., 2016). Fingerprints of the compounds were
examined for any similarity of structural formulas through clus-
tering analysis based on a distancematrix (Figure 4B). After clus-
tering, we could separate the BSIs with similar structures into
one group; for instance, statin-derived BSIs (BSI-Sts) into cluster2308 Cell Reports 21, 2304–2312, November 21, 20173 or aminoquinazoline-based BSIs (BSI-Aqs) into cluster 5. We
could also separate the GSMs with similar structures into one
group; for instance, NSAID-based GSMs (GSM-Ns) into cluster
2 or GSMs with imidazole structure (GSM-Ims) into cluster 8.
For these investigations, we successfully carried out non-biased
chemical structure clustering and classified the compounds and
known Ab-processing modifiers into ten groups (Figure 4C). To
select potent anti-Ab compounds from each group, we selected
the top two compounds from each cluster and investigated
whether dose-dependent reactivity to these compounds could
be seen (Figure 4C). We found 11 compounds with dose-depen-
dency Ab42 reduction and excluded 5 compounds because they
caused massive cell death at higher concentrations of 5–25 mM
(Figure S4B). Finally, six compounds (bromocriptine, cilostazol,
Figure 5. Combination of Anti-Ab Compounds Improved Alz-
heimer’s Disease Phenotypes
Combination of anti-Ab compounds (BCroT) decreased Ab production in a
dose-dependent manner. Data indicate mean ± SD (n = 3 for each clone).
BCroT, combination of bromocriptine, cromolyn, and topiramate.cromolyn, fluvastatin, probucol, and topiramate) that showed
dose-dependent Ab42 reduction and high maximum effect
(Emax) (more than0.25) were chosen as lead compounds (Fig-
ure 4D). All but bromocriptine have been reported to show in vivo
anti-Ab effects (Table S1). However, we identified bromocriptine
as having the most potent anti-Ab effect. We conducted addi-
tional experiments on bromocriptine to investigate the candidate
structure that modifies Ab metabolism. First, we evaluated
various dopamine receptor stimulants and determined that
only bromocriptine, a specific agonist to dopamine receptor
D2 subtype (DRD2), could alter Ab metabolism (Figure S4C).
Next, we compared the effect on Ab metabolism between
DRD2 agonists that include and those that exclude the ergoline
structure. Potent DRD2 agonists without the ergoline structure,
including talipexole and pramipexole, did not alter Ab meta-
bolism (Figure S4D). On the other hand, DRD2 agonists with
the ergoline structure, including bromocriptine, pergolide, and
cabergoline, altered Ab metabolism (Figure S4D). These results
revealed that the ergoline structure, and not the DRD2-agonistic
effect, is important for altering the Ab metabolism of human
neurons. Additionally, we confirmed that compounds with the
ergoline structure, which have a more than 80% structure simi-
larity to bromocriptine, alter Abmetabolism in a dose-dependent
manner (Figure S4E), and we found that the ergot-alkaloid struc-
ture, which contains a tripeptide structure, acts to reduce Ab
production. From these results, our screening system of patient
iPSC-derived neurons could select appropriate hits on the basis
of the anti-Ab effect from a compound library.
A Combination of Three Compounds Can Decrease
Toxic Ab
To maximize the anti-Ab effects, we combined the six lead com-
pounds, all of which have different structures.We analyzed every
possible combination of the six compounds (Figure S5) and iden-
tified a combination of three (bromocriptine, cromolyn, topira-
mate [BCroT]) as the most potent anti-Ab combinations. These
three compounds belonged to different clusters (Figure 4C).
Examining the dose-dependent curves of BCroT for Ab42, wefound a half maximal effective concentration (EC50) value of
1.0 mM, and Emax values exceeding 70% reduction were seen
(Figure 5).
Surveying Pharmacological Responses of Multiple
Individuals
Up to this point, the analysis was conducted using FAD neurons
with the PSEN1G384Amutation (clone name FAD1). To demon-
strate the effect of BCroT on expanded populations, we con-
ducted in vitro studies by using iPSCs from multiple individuals.
We carried out the evaluation by using four additional iPSCs with
AD-causative mutations in PSEN1 or APP (clone name ‘‘FAD’’),
four sporadic AD iPSCs (clone name ‘‘SAD’’), and six control
iPSCs (clone name ‘‘HC’’ or ‘‘Corrected’’) (Figure 6A). The estab-
lished human iPSCs showed pluripotency markers (Figure S6A)
and could be converted into cortical neurons with more than
96%purity (Figures S6B–S6D). The combination of anti-Ab com-
pounds in the cocktail successfully showed more than 30%
reduction in both Ab40 and Ab42 levels in all clones (Figures
6B) and also a reduced high Ab42/40 ratio of PSEN1-mutated
FADs (Figure 6B). From these results, we could highlight the
combination of existing drugs as a new potential anti-Ab cocktail
for AD.
DISCUSSION
In this study, we have developed a robust and rapid method
of neural induction from human iPSCs. Using these cells, we
screened pharmaceutical compounds and found that BCroT
attenuated Ab phenotypes efficiently. Finally, we confirmed the
efficacy of the anti-Ab cocktail using iPSC-derived neurons
from multiple AD patients. Accordingly, we propose a platform
of drug discovery and development using human iPSCs and
compound screening.
Since AD prevention requires early intervention and long-term
usable drugs with validated safety, we screened pharmaceutical
compounds to identify anti-Ab compounds, although hit com-
pounds were predicted to show a relatively weak effect on Ab
metabolism, compared with direct inhibitors of b- or g-secre-
tase. Therefore, we combined screen hits having different action
sites to gain synergistic effects. For this purpose, we conducted
chemical clustering of the hit structures, based on the hypothe-
sis that compounds with different chemical structures target
different molecules. We selected 6 compounds and identified
BCroT as having synergistic anti-Ab effects. These results
suggested that the chemical clustering approach is useful for
determining synergistic combinations of compounds. Addition-
ally, we found that the stimulation of dopamine receptors, which
are targets of bromocriptine, did not alter Ab metabolism, and
we identified the ergoline ring as a key structure for reducing
Ab production. These results indicated that bromocriptine may
reduce the Ab level by modifying the targets of ergot alkaloids
(Wallwey and Li, 2011).
The anti-Ab cocktail of BCroT possessed a potent inhibitory
effect on Ab production in cortical neurons from AD patients
with mutant PSEN1 and effectively diminished toxic Ab to less
than 40%, which is the same level achieved with general BSI
or GSM treatment. At the same time, BCroT showed a modestCell Reports 21, 2304–2312, November 21, 2017 2309
AB
Figure 6. Anti-Ab Cocktail of BCroT Decreased Toxic Ab in Cortical Neurons from a Variety of Individuals
(A) Left: schema of the in vitro trials of BCroT in human iPSC-derived neurons from multiple individuals. BCroT, combination of bromocriptine, cromolyn, and
topiramate. Right: patient information and generated iPSC characters. PBMC, peripheral blood mononuclear cell; FAD, familial Alzheimer’s disease; SAD,
sporadic Alzheimer’s disease; HC, healthy control.
(B) BCroT suppressed the production of Ab40 (left), Ab42 (middle), and the Ab42/40 ratio (right), even in FAD and SAD neurons other than FAD1 neurons. Data
indicate mean ± SD (n = 3 for each clone) (n = 16 clones for each group; *p < 0.05).effect on cortical neurons from sporadic AD and healthy control
iPSCs, with a 20%–30% reduction of toxic Ab levels. A recent
Icelandic genome-cohort study revealed that the APP A673T
mutation located adjacent to the b-cleavage site showed a
20%–30% reduction in Ab production and was resistant to the
onset of AD (Jonsson et al., 2012), suggesting that the modest
effect of the anti-Ab cocktail, BCroT, could be sufficient to pre-
vent AD development if given to preclinical-AD patients. Further-
more, the difference of drug responsiveness between familial AD
with PSEN1mutation and sporadic AD indicates that the individ-
ual genetic background contributes to the responsiveness, and
thus, in the future, personalized compound screening would be
useful for identifying more effective compounds.
In this study, we used pure cortical neurons differentiated
from human iPSCs for the compound screening. This approach
ignores interactions of these neurons with vascular cells, glial
cells, and theblood-brain barrier. For this reason,wewere unable
to translate the anti-Ab effects directly to the clinical study. With
this in mind, mixed cultures of multiple cell types would be valu-2310 Cell Reports 21, 2304–2312, November 21, 2017able for mimicking the complexity of the brain. Furthermore,
whenapplying in vitro results to in vivo efficacy, thebrain bioavail-
ability of orally administered compounds should be considered.
Bromocrpitine and topiramate are known to be efficiently deliv-
ered into brain, and cromolyn can alter brain phenotypes in
various animal models (Hori et al., 2015; San-Martı´n-Clark
et al., 1995). However, pharmacokinetic data of the anti-Ab cock-
tail BCroT are not available, and it is difficult to recapitulate the
absorption, degradation, and clearance of compounds through
the whole body with an in vitro model. In future studies, the
administration of the anti-Ab cocktail BCroT to mice with AD
might provide direct in vivo evidence for feasible clinical trials.EXPERIMENTAL PROCEDURES
Ethical Approval
This study was approved by the Ethics Committee of the Graduate School and
Faculty of Medicine, Kyoto University, and the Kyoto University Hospital
(approval numbers R0091 and G259).
Generation of iN-iPSCs
To establish a robust and rapid differentiation method, we utilized direct con-
version technology. Human NGN2 cDNA, under tetracycline-inducible
promoter (tetO), was transfected into iPSCs by a piggyBac transposon sys-
tem (Kim et al., 2016) and Lipofectamine LTX (Thermo Fisher Scientific,
Waltham, MA). We mainly used the vector containing tetO::NGN2 (Figure 1A)
and, additionally, used another vector containing TetO::NGN2-IRES-mCherry
only to evaluate the time-dependent decrease of the transgenes (Figure S1B).
After antibiotic selection of G418 disulfate (Nacalai-Tesque, Kyoto, Japan), we
picked out colonies and selected subclones that could efficiently differentiate
into neurons by inducing the temporal expression of NGN2, with MAP2/DAPI
purity > 96%.
First-Step Screening
On day 0, iN-iPSCs were dissociated with TrypLE Express (GIBCO, Thermo
Fisher Scientific) and disseminated on a mixed coating of poly-L-lysine
(final 0.0002% v/w, Sigma Aldrich, Japan), Corning Synthemax II-SC (final
20 mg/mL, Corning, NY), and Matrigel (final 2% v/v, Corning). Disseminated
iPSCs were cultured in Neurobasal Medium (GIBCO, Thermo Fisher Scientific)
supplemented with 0.5%B27without vitamin A (GIBCO, Thermo Fisher Scien-
tific), 13 Glutamax (GIBCO, Thermo Fisher Scientific), 2 mg/mL doxycycline
hydrochloride (Wako Pure Chemicals Industries, Japan), and 5 mM Y-27632
(Nacalai-Tesque) from day 0 to day 5. On day 5, differentiated neural cells
were disseminated into 96-well plates by passive humidity control (Nunc
Edge plates, Thermo Fisher Scientific), which can eliminate the evaporation
of culture medium and minimize well-to-well variability. Disseminated neural
cells were cultured in Neurobasal Medium supplemented with 0.5% B27
without vitamin A and 13 Glutamax from day 5 to day 8. On day 8, all
culture media were replaced with 120 mL fresh medium, containing each of
the 2 mM of each compound in final 0.1% DMSO carrier or only 0.1%
DMSO. Neurons or culture media were subjected to analysis 48 hr later.
Pharmaceutical Compound Library
We used theMicrosource International Drug andMicrosource US Drug library,
which includes a total of 1,258 pharmaceutical compounds that have reached
clinical trial stages in the United States. Each compound has been assigned
United States Adopted Names (USAN) or United States Pharmacopeiah
(USP) status and is included in the USP Dictionary. Each 96-well plate
contained 80 compounds per plate, four positive controls for Ab40 (2 mM
BSI-IV), four positive controls for Ab42 and the Ab42/40 ratio (2 mM JNJ-
40418677), and eight negative controls (0.1% DMSO carrier). The raw data
of each compound or positive control were normalized to calculate the alter-
ation ratio by using the average data of the eight DMSO controls in each plate
(the alteration ratio = raw data of each compound/averaged data of eight
DMSO controls in each plate).
Structure-Based Clustering of Chemical Compounds
We prepared a list of additional chemical compounds, including (1) the first-
step screening active compounds (n = 129) and (2) previously reported b- or
g-secretase modifier compounds (n = 55). We classified the total 184 com-
pounds into 10 hierarchical clusters based on similarity (entrusted to Kyoto
Constella Technologies, Japan). The similarity (Tc: Tanimoto coefficient)
among compounds is defined using the ECFP4 fingerprint method (Rogers
and Hahn, 2010), as calculated by jCompoundMapper (Hinselmann et al.,
2011). The distance was defined as ‘‘Distance = 1  Tc.’’ We decided on a
comprehensive distance matrix among all 184 compounds and finally classi-
fied compounds into 10 similar hierarchical clusters by the furthest neighbor
method, using the statistical software tool ‘‘R.’’
Statistical Analysis
All data are indicated as mean ± SD. For comparisons of the mean between
two groups, statistical analysis was performed using a two-tailed Student’s
t test. For comparisons of the mean among more than three groups, statistical
analysis was performed using a one-way ANOVA, followed by a post hoc test
using Dunnett’s test. All analyses were performed by using JMP 9 software
(SAS Institute, Cary, NC). p values < 0.05 were considered significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, one table, and two data files and can be found with this article
online at https://doi.org/10.1016/j.celrep.2017.10.109.
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